10 Year Anniversary Forum on Pathways to Access & Reimbursement - DS

YEARS

ANNIVERSARY

Forum on

PATHWAYS TO ACCESS & REIMBURSEMENT March 26–27, 2025 • One King West, Toronto, ON

Your 2025 Co-Chairs Andrea Masters

Strategic Access & Pricing Director Hoffmann-La Roche Limited

Strengthen Your Market Access Strategy with Timely Insights from: • Canada’s Drug Agency • INESSS • PMPRB • Bayer • Roche • Biogen

Head of Access and Pricing Vertex Pharmaceuticals

Program Highlights CHEVRON-RIGHT Pharmaceutical Policy Power Panel: Hear reflections and projections on the evolution of Canada’s pharmaceutical access environment so that you can plan for 2025 and beyond CHEVRON-RIGHT Technology Use Cases for Pharma: Examine practical applications for managing market access and drug negotiations CHEVRON-RIGHT Hypothetical Case Study and Breakout Discussion: Identify opportunities to improve the drug to market process through patient inclusivity CHEVRON-RIGHT Working Group on how to advance the use of value-based agreements in Canada Associate Sponsors

REGISTER NOW

Rebecca Vieira

CanadianInstitute.com/PathwaystoAccess • 877 927 7936

Networking Breaks Sponsor

a C5 Group Company Business Information in a Global Context

In the 10-year history of the Canadian Institute’s Forum on Pathways to Access and Reimbursement the past year stands out among the rest.

A period of intense change is unfolding. CADTH has transformed into the CDA, the pCPA has transitioned into a standalone organization, and at the federal policy level there is finally movement on funding for drugs for rare disease and the pharmacare file. In addition, the PMPRB has resumed consultations on final guidelines for drug pricing reviews.

Celebrating a Decade of

These changes make for an interesting and complex policy and regulatory environment for pharmaceutical manufacturers to navigate.

Collaborative

CI is proud to continue to offer a platform for government, manufacturers, patients, and payers to come together for critically important conversations about how to ensure patients gain access to the right drug at the right time.

Conversations

Join us in Toronto on March 26–27, 2025, as we celebrate the 10th anniversary of CI’s Forum on Pathways to Access & Reimbursement. As in years prior, the program is curated to ensure that you start the new year with a clear view of Canada’s pharmaceutical landscape.

on Market

The 2025 program will put a strong focus on evidence generation, value-based decision making, expedited pathways to access, and patient perspectives.

Access and

Join us this January, to: CHEVRON-RIGHT BUILD a market access and drug pricing plan based on insights from CDA, INESSS, patients, and industry leaders

Reimbursement

CHEVRON-RIGHT PREPARE for PMPRB’s impending draft guidelines for drug pricing review CHEVRON-RIGHT ALIGN drugs submissions with payer priorities CHEVRON-RIGHT DEVELOP an understanding of how to use AI and digital tools to support market access and drug negotiations CHEVRON-RIGHT COLLABORATE with the life sciences community on strategies to improve the collection and use of RWE for drug access decisions

WHO YOU WILL MEET Practitioners at every level with experience in:

From brand generic and manufacturing companies involved in:

• Pricing

• Policy and compliance

• Product development

• Reimbursement

• Pharmacy services

• Public drug programs

• Market access

• Marketing

• Pharmaceutical benefits

• Patient access

• National trade

• Pharmaceutical strategy

• Government and regulatory affairs

• Formularies

• Drug submissions

• Health economics

• Business development

• Formulary management

• Sales

• Research and development

• Policy and economic analysis • Provider services and • relations • Pharmacy

And representatives from: • Associations

• Patient Advocacy Groups

2 | LINKEDIN Pharmaceuticals, Biotech & Life Sciences: Legal, Regulatory, and Compliance Professionals

Speaker Faculty Co-Chairs Andrea Masters

Strategic Access & Pricing Director Hoffmann-La Roche Limited

Rebecca Vieira

Head of Access and Pricing Vertex Pharmaceuticals

Speakers Saad Ahmed

Suzanne Lepage

Tara Cowling

Private Health Plan Strategist Suzanne Lepage Consulting

President Medlior

Ed Dybka

Sang Mi Lee

General Manager Ipsen Canada

Executive Director Morse Consulting Inc.

Jason Field

Ursula Mann

President and CEO Life Sciences Ontario

Principal and Chief Patient Office PatientVoicePartners

Julie Frappier

President & Founder TOWWERS Program, Data4Actions

Lecturer, Department of Family & Community Medicine University of Toronto

David Greiss

Gail Attara

Bettina Hamelin

Farah Meghji Co-Founder Unum co.

Michael Nashat, PharmD, RPh

Director of Pharmaceutical Partnerships and Operations GreenShield

Director OnPharm-United

President Innovative Medicines Canada (IMC)

Mark Omoto

Head, Market Access & HEOR – Oncology AbbVie

Gerry Jeffcott

Gail Ouellette

Mélanie Caron

Dara​​​​ Jospé

Nathan Sigworth

Farah Jivraj

Robby Spring

President Gastrointestinal Society

Stephane Barakat

Director, Evaluation of Medicines and Technologies for Reimbursement Purposes INESSS

Alex Chambers

Senior Market Access Manager Bayer

Rosemarie Childerhose Head of Market Access & Pricing Biocon Biologics

Guillaume Couillard Executive Director PMPRB

General Manager IQVIA Director Canadian iRARE Centres

Senior Associate 3Sixty Public Affairs

President and Founder CCX

Partner Fasken

Health Innovation, Patient Engagement and Advocacy

Head of Market Access, Policy and Stakeholder Relations Biogen

Mina Tadrous

Assistant Professor, Leslie Dan Faculty of Pharmacy University of Toronto

Sudha Kutty

Executive Vice-President, Evidence, Products, and Services Canada Drug Agency

Durhane Wong-Rieger President & CEO CORD

Philippe Laplante, FICA,FSA Principal Eckler

Global Sponsorship Opportunities

Media Partner

With conferences in the United States, Canada, Latin America and Europe, the C5 Group of Companies: American Conference Institute, Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.

Don’t miss the opportunity to maximize participation or showcase your organization’s services and talent.

For more information please contact us at: SponsorInfo@CanadianInstitute.com

REGISTER NOW

CanadianInstitute.com/PathwaystoAccess • 877 927 7936

a C5 Group Company Business Information in a Global Context

DAY ONE

Wednesday, March 26, 2025 7:45

Registration and Continental Breakfast Served

8:45

Co-Chairs’ Opening Remarks Andrea Masters

Strategic Access & Pricing Director Hoffmann-La Roche Limited

Great overview, gave me a different perspective. Got me thinking differently.

Team Lead, Pricing and Contracts, GSK

Rebecca Vieira

Head of Access and Pricing Vertex Pharmaceuticals

10 YEAR ANNIVERSARY PANEL 9:00

Reflecting on 10 Years in Canada’s Pharmaceutical Landscape: A Progress Report on Promoting Innovation and Improving Patient Access

This special power panel of key stakeholders from across Canada’s pharmaceutical and health care sector will provide reflections and perspectives on the polices and initiatives that have shaped the innovation ecosystem and impacted patient access in Canada. Each panelist will highlight significant strides and persistent barriers to timely access and reimbursement before turning their attention to what’s ahead, with a federal election looming. Key themes to be explore include: • Innovation vs. system sustainability • Unmet patient needs through expedited pathways to access • Progress on pharmacare and anticipating the impact of political shifts

10:00

Bettina Hamelin

Jason Field

President Innovative Medicines Canada (IMC)

President and CEO Life Sciences Ontario

Mark Omoto

Ed Dybka

General Manager IQVIA

General Manager Ipsen Canada

Innovative Pathways to Reimbursement at Canada’s Drug Agency

Sudha Kutty will speak to changes underway at Canada’s Drug Agency in the Reimbursement Review Program. What can you anticipate to see and when. What will change, what will stay the same and what will the impact be.

10:45

Morning Coffee & Networking Break Sponsored by

11:15

Examining Canada’s First Time-Limited Recommendation: Key Takeaways from the Process in Practice for Your Market Access Strategy

Canada’s Drug Agency has granted the first ever time limited reimbursement recommendation to AbbVie for an injectable Lymphoma treatment. The TLR pathway was created by the CDA in collaboration with the pCPA to address unmet patient needs, faster. A temporary recommendation is given based on Phase II clinical data while more evidence collected for future evaluation.

• Navigating the TLR and pTAP process » Outlining the type of drugs that are eligible for the TLR » Identifying potential opportunities to expedite access to drugs in your pipeline with insights on the TLR process in practice • Exploring regulatory and manufacturer perspectives on what worked well and future considerations for the process • Anticipating future expansion of the recommendation category

Sudha Kutty

Executive VicePresident, Evidence, Products, and Services Canada Drug Agency

Sudha Kutty

Executive VicePresident, Evidence, Products, and Services Canada Drug Agency

Stephane Barakat

Head, Market Access & HEOR – Oncology AbbVie

• Examining how RWE will be used to support decision making as part of this pathway

4 | LINKEDIN Pharmaceuticals, Biotech & Life Sciences: Legal, Regulatory, and Compliance Professionals

DAY ONE Wednesday, March 26, 2025 12:00

Lunch Break CASE STUDY

1:15

Shaping the Future of Market Access: Exploring the Role of Technology in Supporting Access and Catalyzing Pharma-Payer Collaboration

Artificial Intelligence holds great potential for the life sciences and pharmaceutical industry in terms of driving innovation and the business.

In market access there is an opportunity to extract insights that will help you stay competitive; however, key processes and platforms need to be in place. This session will explore keys steps in preparing your organization to leverage AI while also providing insights on use cases in market access and drug negotiations.

• Organizing data and implementing processes » Tracking current negotiations » Extract insights from key data points and outcomes for improved negotiations in the future • Identifying opportunities to improve drug pricing negotiation preparation using AI • Assessing the market and establishing the value proposition for innovative new drugs

Sang Mi Lee

Executive Director Morse Consulting Inc.

Andrea Masters

Strategic Access & Pricing Director Hoffmann-La Roche Limited

David Greiss

Director of Pharmaceutical Partnerships and Operations GreenShield

Nathan Sigworth

President and Founder CCX

IMPLEMENTING THE NATIONAL STRATEGY FOR DRUGS FOR RARE DISEASE 2:15

Assessing Future Funding Opportunities through the Common List of Drugs for Rare Disease

In March of 2023, the Government of Canada announced up to $1.5 billion in funding over three years to support the National Strategy for Drugs for Rare Disease. The hope is that this will help lower drug costs and improve patient access. Part of the investment will go to the provinces through bilateral agreement, the first of which, has been made with British Columbia. This session will examine how the strategy is being rolled out and what it means for both patients and the manufacturers who are bringing these innovative therapies to market.

• Detailing how drugs are being evaluated and ultimately selected for the common list • Analyzing how bilateral agreements between the Government of Canada and the provinces will improve access and reduce the funding challenges for DRD • Assessing the role of manufacturers and key stakeholders in RWE collection as part of this process

3:00

Gail Ouellette

MODERATOR:

Farah Jivraj

Head of Market Access, Policy and Stakeholder Relations Biogen

Gerry Jeffcott Senior Associate 3Sixty Public Affairs

Director Canadian iRARE Centres

Durhane Wong-Rieger

President & CEO CORD

Afternoon Networking and Refreshment Break Sponsored by CASE STUDY AND BREAKOUT DISCUSSION

3:30

Pinpointing Missed Opportunities to Engage Patients and Enhance Decisions Making about Drugs

This interactive session will use a hypothetical product launch case study as the basis for discussions about data gaps and how patient experiences and insights can support and solve challenges along the pathways to access.

4:45

Robby Spring

Health Innovation, Patient Engagement and Advocacy

Cheers to 10 Years!

Join us for a special prosecco pour to cap off day one of the conference. Together we will raise a glass to 10 years of collaborative conversations at CI's Forum Pathways to Access and Reimbursement.

REGISTER NOW

CanadianInstitute.com/PathwaystoAccess • 877 927 7936

a C5 Group Company Business Information in a Global Context

DAY TWO

Overall excellent topics and speakers.

Truly enjoyed the selection of speakers and the panels.

Thursday, March 27, 2025 7:45

Registration Opens and Continental Breakfast Served

8:45

Co-Chairs' Opening Remarks Andrea Masters

Strategic Access & Pricing Director Hoffmann-La Roche Limited

9:00

Manager, Pricing and Contracts, Astellas

Rebecca Vieira

Head of Access and Pricing Vertex Pharmaceuticals

The Value Based Drug Pricing Showcase in Quebec: A Collaborative Data Project to Expedite Drug Access in Canada

Creating equitable access to innovative new medicines is critical.

Breakthrough treatments can be life changing, and even lifesaving for patients but without sufficient data and the necessary infrastructure it can be difficult for payers to make reimbursement decisions.

To tackle this challenge, a multi-stakeholder group has come together to advance the implementation of value-based pricing in Canada through a series of demonstration projects. The initiative, led by patients, physicians, payers, policymakers and manufacturers, will collect data on and evaluate the value of a drug at a patient and health system level.

Julie Frappier

Alex Chambers

President & Founder TOWWERS Program, Data4Actions

Senior Market Access Manager Bayer

Ursula Mann

Tara Cowling

Principal and Chief Patient Office PatientVoicePartners

President Medlior

This session will provide insights on the project and future deliverables aimed at supporting drug decisions.

10:15

Anticipating PMPRB Draft Guidelines: How to Prepare for Future Drug Pricing Reviews in Canada

PMPRB recently invited stakeholders to comment on a discussion guide outlining the proposed framework for drug price reviews that will make up new guidelines.

• Overview of the proposed framework including international price comparison (IPC) options: » Median International Price (MIP)

Guillaume Couillard Executive Director PMPRB

» Highest International Price (HIP) » The midpoint between MIP and HIP • Demonstrating how different pricing options will be applied in reviews using case study examples • Anticipating the impact of different pricing options on innovator drug companies and patient access • Assessing how grandfathered patented medicines will be impacted under the new framework

10:45

Morning Coffee & Networking Breaks Sponsored by SPECIAL FOCUS ON QUEBEC

11:00

INESSS: Aligning Market Access Strategies with Pharmaceutical Reviews in Quebec Mélanie Caron QUEBEC CASE STUDY

11:45

Director, Evaluation of Medicines and Technologies for Reimbursement Purposes INESSS

Navigating Drug Negotiation Grey Areas in Canada

What happens when you are not successful in negotiating an LOI with the pCPA? Can individual jurisdictions negotiate independently? And what happens when they refuse to do so? A judicial review is currently being brought in Quebec to explore these issues.This session will detail that judicial review and the pseudo-administrative framework which led to the court action.

Dara​​​​ Jospé Partner Fasken

6 | LINKEDIN Pharmaceuticals, Biotech & Life Sciences: Legal, Regulatory, and Compliance Professionals

DAY TWO Thursday, March 27, 2025 12:15

Lunch Break

1:15

Preferred Pharmacy Network: Assessing the Pros, Cons, and Projected Impact of Patient Access

Ontario’s Ministry of Finance is consulting on the role of preferred pharmacy networks (PPN) in Ontario’s employer-sponsored drug insurance industry following push back from patient groups and industry associations.

For the insurance companies entering into these contractual agreements that allow only specific pharmacies to provide services to members, the argument is that it will lower costs. However, there are concerns that PPNs disrupt care and jeopardize patient access. This session will focus on: • Defining the role of preferred pharmacy networks » Understanding the different network designs • Weighing the pros and cons of PPNs

Suzanne Lepage

Private Health Plan Strategist Suzanne Lepage Consulting

Michael Nashat, PharmD, RPh Director OnPharm-United

» Assessing the impact on patient access and the overall health system » Addressing concerns that PPNs are anticompetitive • Examining current regulations for PPNs in Ontario and the rest of Canada » Anticipating how the regulatory environment could evolve because of Ontario’s consultation process

2:00

Next Steps in Addressing Supply Chain Disruptions and Drug Shortages in Canada

Since the pandemic, disruptions to the pharmaceutical supply chain have been exacerbated.

A multi-stakeholder group in Canada is working diligently to mitigate the impact on patients.

Significant strides towards monitoring and managing drugs supply has been made with the creation of a tracking system for critical drugs. Those are the shortages or discontinuation events are expected to have the highest impact on Canada drug supply and the overall health system.

• Examining the newly established national drug shortage list and how it will be used to communication and act on potential shortages in the future • Assessing current supply chain challenges impacting drug supply in Canada • Identifying how stakeholders across the pharmaceutical supply chain and in the health care system can assist with the prevention and mitigation of drug shortages

Saad Ahmed

Lecturer, Department of Family & Community Medicine University of Toronto

Mina Tadrous

Assistant Professor, Leslie Dan Faculty of Pharmacy University of Toronto

• Exploring how artificial intelligence can assist with real time monitoring

2:45

Afternoon Networking and Refreshment Break Sponsored by

3:00

Special Focus on Inequity in Drug Access: Comparing Public Coverage in BC with the Rest of Canada

A report developed by the Gastrointestinal Society reveals inequities in drug access across Canada. According to the analysis, British Columbia is not keeping up with drug other drug budgets and has denied coverage of critical medications approved by other provinces.

This session will take a deep dive into gaps in spending and the patient impact.

3:45

Gail Attara

President Gastrointestinal Society

Drug Pooling: Examining the Ins and Outs of the Private Payer Framework to Manage High-Cost Claims

• Understanding how drug insurance pooling is used in Canada to manage offset the impact of high-cost drug claims » Understanding the finer actuarial considerations for measuring risk • Identifying the provincial differences in the implementation of pooling • Assessing the ability of pooling to manage multiple or recurring high-cost drug claims

Philippe Laplante, FICA,FSA Principal Eckler

• Understanding plan sponsor perspectives on pooling • Forecasting the future of pooling frameworks

4:30

Conference Concludes

REGISTER NOW

CanadianInstitute.com/PathwaystoAccess • 877 927 7936

a C5 Group Company Business Information in a Global Context

Stay Ahead of the Curve: Gain Insights at C5's Premier Healthcare & Life Science Events!

February 20 – 21, 2025 • New York, NY

July 30 – 31, 2025 • Boston, MA

June 19 – 20, 2025 • Vancouver, BC

The C5 Group, comprising American Conference Institute, the Canadian Institute and C5 in Europe, is a leading global events and business intelligence company.

For over 40 years, C5 Group has provided the opportunities that bring together business leaders, professionals and international experts from around the world to learn, meet, network and make the contacts that create the opportunities.

Our conferences and related products connect the power of people with the power of information, a powerful combination for business growth and success.

Join Our Email List to Stay Connected SIGN UP TO RECEIVE EXCLUSIVE DISCOUNTS, OFFERS AND PROGRAM UPDATES CanadianInstitute.com/elist/

8 | LINKEDIN Pharmaceuticals, Biotech & Life Sciences: Legal, Regulatory, and Compliance Professionals

VENUE INFORMATION

One King West Hotel 1 King Street West, Toronto, ON M5H 1A1 Phone: 1-866-470 KING (5464) ACCOMMODATIONS The Canadian Institute is pleased to offer our delegates a limited number of hotel rooms at a negotiated rate. To take advantage of these rates, please contact the hotel directly and quote "CI’s Pathways to Access & Reimbursement”.

Reservations: 1-866-470 KING (5464) or reservations@onekingwest.com

WORRY FREE Registration

GUARANTEE

Book with Confidence!

Register and pay to lock in your early rate and be eligible for a full refund until January 16, 2025.

If you are unable to attend for any reason, you will have the following options: y A full credit note for you, or a colleague to attend another event. y A full refund.

All cancellations and changes must be submitted to CustomerService@CanadianInstitute.com by January 16, 2025.

Mark Parrish, Canadian Institute

Looking to Register?

Contact our Customer Service Representatives:



M.Parrish@CanadianInstitute.com



647 696 2397

Use Registration Code: B00-999-MPH25

PRICING

Gonzalo Dounis, Canadian Institute 

G.Dounis@CanadianInstitute.com



289 498 2791

Use Registration Code: B00-999-GDS25

Register & Pay after December 13, 2024

CONFERENCE CODE:

$2695

Bringing a Team?*

350X25-TOR

*APPLICABLE TAXES WILL BE ADDED TO ALL REGISTRATIONS Conference All program participants will receive an online link to access the conference materials as part of their registration fee.

Additional copies of the Conference Materials available for $199 per copy.

To update your contact information and preferences, please visit https://www.CanadianInstitute.com/preference-center/.

Terms & conditions and refund/cancellation policies can be found at CanadianInstitute.com/company/faq/

© Canadian Institute, 2024

1–3

No Discount

4–8

10% Conference Discount

9–12

15% Conference Discount

12+

Call 877-927-0718

* Team/group registrations must be from the same organization/firm and register together in one transaction.